This week, FDA approved two novel multiple myeloma therapies after fast, four-month reviews: Takeda Pharmaceutical Co. Ltd. 's Ninlaro (ixazomib) and Johnson & Johnson /Genmab AS's breakthrough-designated Darzalex (daratumumab).
A four-month reivew is an internal goal often set by the Office of Hematology and Oncology Products for products that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?